@article{9c7d18b3b7d04539a56ef76703302fc9,
title = "Utilization of covid-19 treatments and clinical outcomes among patients with cancer: A covid-19 and cancer consortium (ccc19) cohort study",
abstract = "Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARS-CoV-2 infection, we examined the association of COVID-19 treatments with 30-day all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19 treatment other than hydroxychloroquine or untreated controls; this association was not present with hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled trials. SIGnIfICAnCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a large observational study, there was no statistically significant 30-day all-cause mortality benefit with hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential benefit. Treatment receipt reflects clinical decision-making and suggests disparities in medication access.",
author = "{COVID-19 and Cancer Consortium} and Rivera, {Donna R.} and Solange Peters and Panagiotou, {Orestis A.} and Shah, {Dimpy P.} and Kuderer, {Nicole M.} and Hsu, {Chih Yuan} and Rubinstein, {Samuel M.} and Lee, {Brendan J.} and Choueiri, {Toni K.} and Lopes, {Gilberto de Lima} and Petros Grivas and Painter, {Corrie A.} and Rini, {Brian I.} and Thompson, {Michael A.} and Jonathan Arcobello and Ziad Bakouny and Doroshow, {Deborah B.} and Egan, {Pamela C.} and Dimitrios Farmakiotis and Fecher, {Leslie A.} and Friese, {Christopher R.} and Galsky, {Matthew D.} and Sanjay Goel and Shilpa Gupta and Halfdanarson, {Thorvardur R.} and Balazs Halmos and Hawley, {Jessica E.} and Khaki, {Ali Raza} and Lemmon, {Christopher A.} and Sanjay Mishra and Olszewski, {Adam J.} and Pennell, {Nathan A.} and Puc, {Matthew M.} and Revankar, {Sanjay G.} and Lidia Schapira and Andrew Schmidt and Schwartz, {Gary K.} and Shah, {Sumit A.} and Wu, {Julie T.} and Zhuoer Xie and Yeh, {Albert C.} and Huili Zhu and Yu Shyr and Lyman, {Gary H.} and Warner, {Jeremy L.}",
note = "Funding Information: This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE; to D.P. Shah); the Jim and Carol O{\textquoteright}Hare Fund (to S.M. Rubinstein); the NCI (P30 CA013696, to J.E. Hawley; P30 CA054174, to D.P. Shah; P30 CA068485, to C.-Y. Hsu, B.I. Rini, J.L. Warner, S. Mishra, and Y. Shyr; P30 CA196521, to D.B. Doroshow and M.D. Galsky; T32 CA009515, to A.R. Khaki; T32 CA203703, to J.E. Haw-ley; UG1 CA189828, to O.A. Panagiotou; UG1 CA189974, to G.H. Lyman; and U01 CA231840, to J.L. Warner); and the National Human Genome Research Institute (T32 HG008341, to S.M. Rubinstein). REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Funding Information: This study was partly supported by grants from the American Cancer Society and Hope Foundation for Cancer Research (MRSG-16-152-01-CCE; to D.P. Shah); the Jim and Carol O?Hare Fund (to S.M. Rubinstein); the NCI (P30 CA013696, to J.E. Hawley; P30 CA054174, to D.P. Shah; P30 CA068485, to C.-Y. Hsu, B.I. Rini, J.L. Warner, S. Mishra, and Y. Shyr; P30 CA196521, to D.B. Doroshow and M.D. Galsky; T32 CA009515, to A.R. Khaki; T32 CA203703, to J.E. Hawley; UG1 CA189828, to O.A. Panagiotou; UG1 CA189974, to G.H. Lyman; and U01 CA231840, to J.L. Warner); and the National Human Genome Research Institute (T32 HG008341, to S.M. Rubinstein). REDCap is developed and supported by Vanderbilt Institute for Clinical and Translational Research grant support (UL1 TR000445 from NCATS/NIH). The funding sources had no role in the writing of the manuscript or the decision to submit it for publication. Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",
year = "2020",
doi = "10.1158/2159-8290.CD-20-0941",
language = "English (US)",
volume = "10",
pages = "1514--1527",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "10",
}
